Phase 4Active, not recruiting

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR)

Sponsor
Cedars-Sinai Medical Center (Academic or other)
Enrollment
2,476 enrolled
Conditions
Coronary Artery Disease
Interventions
High dose potent statin; ACE-I (lisinopril) or ARB (losartan); Aspirin 81 enteric coated tablet daily; Lifestyle Counseling; Quality of Life Questionnaires
Ages
adults, older adults
Registry
NCT03417388

Full record on ClinicalTrials.gov

From the registry

The Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) evaluating intensive statin/ACE-I (or ARB)/aspirin treatment (IMT) vs. usual care (UC) in 4,422 symptomatic women patients with symptoms and/or signs of ischemia but no obstructive CAD. The hypothesis is that IMT will reduce major adverse coronary events (MACE) 20% vs. UC. The primary outcome is first occurrence of MACE as death, nonfatal MI, nonfatal stroke/transient ischemic attack (TIA) or hospitalization for heart failure or angina. Secondary outcomes include quality of life, time to "return to duty"/work, health resource consumption, angina, cardiovascular (CV) death and primary outcome components. Events will be adjudicated by an experienced Clinical Events Committee (CEC). Follow-up was planned to be 3-years using 50 sites: primarily VA and Active Duty Military Hospitals/Clinics and a National…

Primary outcomes

  • The primary outcome is MACE, defined as first occurrence of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for angina or HF.

History

  1. Study completion expected

  2. Completion moved to Feb 15, 2025

    , from May 31, 2024 to Feb 15, 2025

  3. Last registry update

  4. Primary completion

  5. Started

  6. Registered